You're right. It is... so could be any time.This is Q4 bro. I'm hoping something happens this month.
Sorry to ask, does this mean that their trials have been successful? Could any of these be coming out in 3 years?
They haven't even started any trials for FX-345 yet. FX-322 will have results for Phase 2 early next year. If the results are amazing, then they will launch it ASAP. If results are good, then they do a Phase 3 and it will be 2 or 3 years till it gets to market from there. If it fails, then that's probably the end of the entire company.Sorry to ask, does this mean that their trials have been successful? Could any of these be coming out in 3 years?
Are they able to bypass Phase 3 completely if they have Breakthrough/Fast Track designation, provided great results next year? I can't find anything really for that through searching internet results. Then FDA NDA applications take around a year for review; quicker with accelerated approval.They haven't even started any trials for FX-345 yet. FX-322 will have results for Phase 2 early next year. If the results are amazing, then they will launch it ASAP. If results are good, then they do a Phase 3 and it will be 2 or 3 years till it gets to market from there. If it fails, then that's probably the end of the entire company.
It has Fast Track no matter what, but it can skip Phase 3 if results are exceptional. I am not going to get too excited about it because there's definitely a chance it could fail too.Are they able to bypass Phase 3 completely if they have Breakthrough/Fast Track designation, provided great results next year? I can't find anything really for that through searching internet results. Then FDA NDA applications take around a year for review; quicker with accelerated approval.
Hoping they see tinnitus as a life threatening/serious disease and grant the accelerated status since it is a secondary outcome. Even the primary measurement, word recognition, could be construed as life threatening and serious in certain situations. Like in the military for example, the soldiers would have a better understanding of instructions by the Sergeant, which in itself is life/death, like enemy coordinates.
The tradition used to be that you needed 2 pivotal trials in order to apply for FDA approval but, over the last 15 years or so, approximately 53% of new drugs today get approved by the FDA with only 1 pivotal trial. FX-322-208 is going to be considered a pivotal trial so there is a small chance the FDA could tell them that they can apply for NDA upon a successful readout. They already have Fast Track status which cuts FDA review time down from 1 year to 6 months.Are they able to bypass Phase 3 completely if they have Breakthrough/Fast Track designation, provided great results next year? I can't find anything really for that through searching internet results. Then FDA NDA applications take around a year for review; quicker with accelerated approval.
Biotechs operate year round. If they didn't run trials during holiday season, then they would just be sitting and waiting while burning cash daily.I guess no news for October. I didn't think they generally started trials during the holiday season, so I'm not sure what to expect for November and December.
Johns Hopkins is running a trial during the holiday season for PTSD. They run trials during the holidays.I guess no news for October. I didn't think they generally started trials during the holiday season, so I'm not sure what to expect for November and December.
I went on ClinicalTrials.gov and couldn't find it. I wonder when they plan on rolling out trials.
The news just keeps getting better and better. Hopefully it makes it all the way through.
Very exciting indeed!
As long as they still release FX-322 out in the market first (with FX-345 still in clinical trials), it will be good. I hope they don't hold back FX-322 where it could help the majority of us here and have to wait for FX-345 to come out.I thought they were going to wait until they had the results for the FX-322 trial but maybe the results have been good for that. I can't see how they would be starting this without knowing the base drug had good results.
There's no chance of that happening in my mind. They want FX-322 on the market ASAP.As long as they still release FX-322 out in the market first (with FX-345 still in clinical trials), it will be good. I hope they don't hold back FX-322 where it could help the majority of us here and have to wait for FX-345 to come out.
They need cash flow. They are not going to wait.As long as they still release FX-322 out in the market first (with FX-345 still in clinical trials), it will be good. I hope they don't hold back FX-322 where it could help the majority of us here and have to wait for FX-345 to come out.
There's no chance of that happening in my mind. They want FX-322 on the market ASAP.
The results of the latest trial will be out in about 3 months. I'd be surprised if the results weren't good.
I hope that's the case. I was surprised when they announced the 1st dosing of FX-345 when the results of the Phase 2b FX-322 hadn't come out yet.They need cash flow. They are not going to wait.
FX-322 and FX-345 are different drugs, I'm not sure why you think they would wait for results of the former.I hope that's the case. I was surprised when they announced the 1st dosing of FX-345 when the results of the Phase 2b FX-322 hadn't come out yet.
Originally they were going to start the FX-345 trial in October but, with the delayed results of Phase 2b FX-322, I guess they must have decided to go ahead with it once they found out the results were positive with the current FX-322 trial. I hope their reason for starting the FX-345 trial is not because the results were negative in the current FX-322 trial.
They are different but very similar. If FX-322 doesn't work, then there's little chance that FX-345 will. Regardless of that point, if FX-322 doesn't work, then they probably won't have enough funding to go ahead with FX-345.FX-322 and FX-345 are different drugs, I'm not sure why you think they would wait for results of the former.
It does seem like they're going ahead with this trial because the latest FX-322 results are good but that's a lot of assumptions.I hope that's the case. I was surprised when they announced the 1st dosing of FX-345 when the results of the Phase 2b FX-322 hadn't come out yet.
Originally they were going to start the FX-345 trial in October but, with the delayed results of Phase 2b FX-322, I guess they must have decided to go ahead with it once they found out the results were positive with the current FX-322 trial. I hope their reason for starting the FX-345 trial is not because the results were negative in the current FX-322 trial.
The results of FX-345 are not contingent on the results of FX-322. The company always intended to conduct the FX-345 trial regardless of the results of FX-322.I hope that's the case. I was surprised when they announced the 1st dosing of FX-345 when the results of the Phase 2b FX-322 hadn't come out yet.
Originally they were going to start the FX-345 trial in October but, with the delayed results of Phase 2b FX-322, I guess they must have decided to go ahead with it once they found out the results were positive with the current FX-322 trial. I hope their reason for starting the FX-345 trial is not because the results were negative in the current FX-322 trial.
Not working and failing to reach statistical significance are 2 different things. If FX-322 doesn't work, it means the compound has no effect on cochlear hair cells. If it fails to cause stat sig improvements, it means that it may still be working but it isn't penetrating deep enough into the cochlea to show stat sig improvements and that's where FX-345's deeper cochlear penetration could make a difference. The company has enough money to see the FX-345 trial results regardless of the FX-322 trial results.They are different but very similar. If FX-322 doesn't work, then there's little chance that FX-345 will. Regardless of that point, if FX-322 doesn't work, then they probably won't have enough funding to go ahead with FX-345.
When I say not work, I mean failing the trials.Not working and failing to reach statistical significance are 2 different things.
In that case, then I will have to disagree with the statement you made saying "If FX-322 doesn't work, then there's little chance that FX-345 will." The whole point of FX-345 is to potentially produce more efficacious response in more patients compared to FX-322.When I say not work, I mean failing the trials.
Yeah, I disagree with my original statement too. Probably just less chance of FX-345 passing the clinical trial if FX-322 fails in the clinical trial, but not impossible for FX-345 to pass if FX-322 fails.In that case, then I will have to disagree with the statement you made saying "If FX-322 doesn't work, then there's little chance that FX-345 will." The whole point of FX-345 is to potentially produce more efficacious response in more patients compared to FX-322.